Skip to main content
    P

    Palvella Therapeutics, Inc (PVLA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $127.34
    +4.76 (+3.88%)

    Market Cap: $1.77B

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    9%(3/34)
    Avg Surprise
    -4071.78%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-1.74
    Range$-2.31 - $-1.05
    12 analysts
    EPS RevisionsNo revisions (7d)
    0
    1
    30d
    EPS Estimate DriftChange to current
    90d ago$-1.47-18.9%
    60d ago$-1.47-18.9%
    30d ago$-1.74-0.4%
    7d ago$-1.74-0.4%
    Current$-1.74
    Revenue Consensus
    $0
    Range$0 - $0
    14 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-2.60
    Range$-4.02 - $-0.13
    12 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    14 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-2.60---
    Sep 26EST
    		-$-1.74---
    Jun 26
    Reported Aug 4
    		$-1.52$-1.16-31.03%Miss-76.7%
    Mar 26
    Reported May 7
    		$-1.20$-0.93-29.03%Miss-62.2%
    Dec 25
    Reported Mar 31
    		$-1.08$-0.91-18.58%Miss+79.9%
    Sep 25
    Reported Nov 11
    		$-1.03$-0.85-21.18%Miss+52.9%
    Jun 25
    Reported Aug 14
    		$-0.86$-0.77-11.69%Miss+68.9%
    Mar 25
    Reported May 15
    		$-0.74N/A+78.24%Beat+81.3%
    Dec 24
    Reported Mar 31
    		$-5.37$-0.60-798.74%Miss-44.9%
    Sep 24
    Reported Nov 13
    		$-2.19N/AN/ABeat+74.9%
    Jun 24
    Reported Aug 14
    		$-2.76$-0.03-9112.33%Miss-169.1%
    Mar 24
    Reported May 15
    		$-3.95$-0.06-6491.17%Miss+72.5%
    Dec 23
    Reported Mar 29
    		$-3.71$-0.12-2988.92%Miss+57.9%
    Sep 23
    Reported Nov 14
    		$-8.70$-0.11-7810.45%Miss+16.3%
    Jun 23
    Reported Aug 10
    		$4.00$-0.16+2652.65%Beat+135.7%
    Mar 23
    Reported May 10
    		$-14.40$-0.18-7747.41%Miss-157.1%
    Dec 22
    Reported Mar 29
    		$-8.80$-0.23-3726.09%Miss+26.7%
    Sep 22
    Reported Nov 2
    		$-10.40$-0.16-6400.00%Miss+45.8%
    Jun 22
    Reported Aug 4
    		$-11.20$-0.11-10081.82%Miss+44.0%
    Mar 22
    Reported May 11
    		$-5.60$-0.12-4769.57%Miss+0.0%
    Dec 21
    Reported Mar 1
    		$-12.00$-0.14-8788.89%Miss+42.3%
    Sep 21
    Reported Nov 2
    		$-19.20$-0.24-7791.49%Miss+7.7%
    Jun 21
    Reported Aug 4
    		$-20.00$-0.22-8990.91%Miss-177.8%
    Mar 21
    Reported May 17
    		$-5.60$-0.17-3194.12%Miss+0.0%
    Dec 20
    Reported Mar 30
    		$-20.80$-0.23-8846.24%Miss-333.3%
    Sep 20
    Reported Nov 4
    		$-20.80$-0.13-15900.00%Miss-420.0%
    Jun 20
    Reported Aug 10
    		$-7.20$-0.17-4135.29%Miss+62.5%
    Mar 20
    Reported May 11
    		$-5.60$-0.17-3194.12%Miss+65.0%
    Dec 19
    Reported Mar 12
    		$-4.80$-0.28-1614.29%Miss+72.7%
    Sep 19
    Reported Nov 11
    		$-4.00$-0.17-2252.94%Miss+54.5%
    Jun 19
    Reported Aug 7
    		$-19.20$-0.22-8627.27%Miss-6283.0%
    Mar 19
    Reported May 8
    		$-16.00$-0.20-7900.00%Miss-9311.8%
    Dec 18
    Reported Mar 20
    		$-17.60$-0.18-9677.78%Miss-222.2%
    Sep 18
    Reported Nov 7
    		$-8.80$-0.12-7233.33%Miss+30.8%
    Jun 18
    Reported Aug 9
    		$-0.30$-0.01-2908.00%Miss+98.4%
    Mar 18
    Reported May 10
    		$-0.17$-0.02-750.00%Miss+98.9%
    Dec 17
    Reported Mar 9
    		$14.40$-0.07+20671.43%Beat+218.2%
    Sep 17
    Reported Nov 9
    		$-12.72N/AN/ABeat-
    Jun 17
    Reported Aug 10
    		$-18.59N/AN/ABeat-
    Mar 17
    Reported May 11
    		$-14.85N/AN/ABeat-
    Dec 16
    Reported Mar 23
    		$-12.19N/AN/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-26.36EV/EBITDAN/A
    Price/FCF-50.07xFCF Yield-2.00%
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-46.60%ROICN/A
    Financial Health
    Debt/EquityN/AInterest Coverage-7.12x
    Current Ratio21.18xQuick Ratio21.18x
    Trading Statistics
    BetaN/AAvg Volume243.85K
    52-Week High$161.3852-Week Low$68.96

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$130.61
    SMA 20$137.58
    SMA 50$146.14
    SMA 200$125.10
    EMA 10$131.21
    EMA 20$135.87
    EMA 50$140.82
    EMA 200$123.55

    MACD

    Line: -5.56Signal: -4.69Hist: -0.87

    ADX

    ADX: 25.3+DI: 13.4-DI: 27.6

    Aroon & PSAR

    Aroon Up32.0
    Aroon Down96.0
    PSAR$139.47

    Bollinger Bands

    Upper Band$156.75
    Lower Band$118.40
    %B Position2788%(Upper)
    Band Width0.23

    RSI (14-Day)

    Neutral
    38.6

    Momentum Oscillators

    Stoch %K18.4
    Stoch %D21.7
    Williams %R-69.6
    ROC (10d)-4.1%
    Momentum-5.39
    CCI (20d)-95.6
    MFI (14d)30.5

    Volatility Measures

    ATR (14d)$7.22(5.7%)
    StdDev (20d)9.59
    Hist Vol50.9%(High)

    Volume Flow

    VWAP$126.45
    OBV6.9M
    AD Line5.1M
    CMF (20d)-0.179

    Volume Metrics

    Avg Vol (20d)250.2K
    Vol Ratio1.0x
    VWMA (20d)$137.68

    Pivot Points

    R3$135.18
    R2$131.73
    R1$127.16
    Pivot Point$123.71
    S1$119.14
    S2$115.69
    S3$111.12

    Advanced Oscillators

    TSI-24.96
    Ultimate Osc55.5
    KST-126.47

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$0$0$0$53,000$1.30M$19.52M
    Cost of RevenueN/AN/AN/AN/AN/AN/AN/AN/AN/A$-30,000N/A$739,000
    Gross ProfitN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A$1.30M$18.78M
    Operating Expenses$21.41M$14.86M$11.30M$10.18M$9.25M$7.87M$4.37M$5.06M$2.91M$1.76M$6.78M$15.70M
    R&D$12.47M$9.33M$7.12M$6.53M$5.12M$4.07M$2.54M$3.20M$1.44M$984,000$4.45M$9.60M
    SG&A$8.93M$5.52M$4.18M$3.65M$4.13M$3.80M$1.82M$1.88M$1.47M$775,000$0$0
    Operating Income$-21,405,000$-14,855,000$-11,304,000$-10,177,000$-9,250,000$-7,871,000$-4,366,000$-5,062,000$-2,908,000$-1,759,000$-5,482,000$3.09M
    Interest Income$1.97M$1.07M$520,000$628,000$690,000$752,000$0$187,000$0$86,000$0$0
    Interest Expense$2.31M$2.04M$1.74M$1.51M$1.35M$1.22M$1.30M$1.24M$1.06M$805,000$0$13.84M
    Income Before Tax$-21,870,000$-15,767,000$-12,714,000$-11,345,000$-9,471,000$-8,185,000$-3,951,000$-6,775,000$-4,172,000$-2,536,000$-4,584,000$-10,752,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-21,870,000$-15,767,000$-12,714,000$-11,345,000$-9,471,000$-8,185,000$-3,951,000$-6,775,000$-4,172,000$-2,536,000$-4,584,000$-10,752,000
    EBITDA$-21,562,000$-17,806,000$-10,975,000$342,000$-8,117,000$-6,970,000$-2,647,000$-1,713,000$-3,115,000$-1,731,000$-4,584,000$-10,013,000
    EBIT$-19,562,000$-13,728,000$-10,975,000$-9,835,000$-9,250,000$-7,871,000N/A$-6,775,000$-4,176,999$-1,701,000$-5,482,000$-10,752,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about PVLA

    News

    Palvella Therapeutics Announces Pediatric Analyses of QTORIN Rapamycin Showing Improvements in Rare Vascular Malformations

    Palvella Therapeutics announced positive pediatric analyses from its Phase 3 SELVA and Phase 2 TOIVA clinical studies of QTORIN™ rapamycin. The findings...

    Quiver Quantitative•10/15/26•Somewhat-Bullish

    Under a trading plan, George M. Jenkins sold 27,500 shares of Palvella Therapeutics (PVLA).

    George M. Jenkins, a director at Palvella Therapeutics (PVLA), sold a total of 27,500 shares of common stock across three days in October 2026. These transactions were executed under a Rule 10b5-1 trading plan...

    Stock Titan•10/14/26•Neutral

    Analysts Offer Insights on Healthcare Companies: Pfizer (PFE), Palvella Therapeutics (PVLA) and Mineralys Therapeutics, Inc. (MLYS)

    The article provides an overview of recent analyst ratings for three healthcare companies: Pfizer (PFE), Palvella Therapeutics (PVLA), and Mineralys Therapeutics...

    The Globe and Mail•10/13/26•Bullish

    Palvella Therapeutics to Participate in the Chardan 10th Annual Healthcare Conference

    Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on rare skin diseases, announced its participation in the Chardan 10th Annual Healthcare Conference. Members of its management team will...

    GlobeNewswire•10/13/26•Somewhat-Bullish

    Palvella presents data on rapamycin gel, DSAP patient analysis By Investing.com

    Palvella Therapeutics Inc. presented findings from its Phase 3 SELVA study of QTORIN rapamycin gel for microcystic lymphatic malformations, a pharmacokinetic substudy...

    Investing.com South Africa•10/12/26•Bullish

    PVLA Valuation and Fair Value

    P/E
    -26.4x
    P/FCF
    -50.1x
    P/B
    8.4x
    See GNG's fair value

    PVLA Profitability: Margins, ROIC and FCF

    Operating margin
    0.0%
    Net margin
    0.0%
    ROE
    -46.6%
    FCF yield
    -2.0%

    PVLA Competitors

    CompanyTicker
    Sarepta Therapeutics IncSRPT
    Vir Biotechnology IncVIR
    Xeris Pharmaceuticals IncXERS
    Xencor IncXNCR
    Galapagos NV ADRGLPG
    Sonida Senior Living IncSNDA
    Mineralys Therapeutics, Inc. Common StockMLYS
    Alignment Healthcare LLCALHC

    Sector: Healthcare

    PVLA Analyst Ratings

    Consensus
    Buy
    Analysts
    15
    Strong Buy
    0
    Buy
    15
    Hold
    0
    Sell
    0
    Strong Sell
    0

    PVLA Bull Case vs Bear Case

    Bull case

    • 100.0% of PVLA's analyst ratings are Buy or Strong Buy.

    Bear case

    • PVLA beat EPS estimates in 12.5% of its last 8 reported quarters.

    PVLA Earnings: Beat Rate and Next Report

    Beat rate
    1 of 8 quarters (12.5%)
    Average surprise
    -1243.0%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-1.74
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    0 up, 1 down

    Frequently Asked Questions About PVLA

    Does PVLA pay dividends?

    Palvella Therapeutics, Inc (PVLA) does not currently pay a regular dividend.

    What is PVLA's market cap?

    Palvella Therapeutics, Inc (PVLA) has a market capitalization of $1.77B with a current stock price of $127.34.

    Related stocks

    Sector: Healthcare

    All stocks starting with P

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In